{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T17:48:37Z","timestamp":1759513717754,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T00:00:00Z","timestamp":1632096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T00:00:00Z","timestamp":1632096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","award":["2016-I2M-1-001"],"award-info":[{"award-number":["2016-I2M-1-001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study aimed to recognize the hub genes associated with prognosis in follicular lymphoma (FL) treated with first-line rituximab combined with chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>RNA sequencing data of dataset GSE65135 (n\u2009=\u200924) were included in differentially expressed genes (DEGs) analysis. Weighted gene co-expression network analysis (WGCNA) was applied for exploring the coexpression network and identifying hub genes. Validation of hub genes expression and prognosis were applied in dataset GSE119214 (n\u2009=\u2009137) and independent patient cohort from Cancer Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College (n\u2009=\u200932), respectively, by analyzing RNAseq expression data and serum protein concentration quantified by ELISA. The Gene Set Enrichment Analysis (GSEA), gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichments analysis were performed. CIBERSORT was applied for tumor-infiltrating immune cells (TIICs) subset analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 3260 DEGs were obtained, with 1861 genes upregulated and 1399 genes downregulated. Using WGCNA, eight hub genes, <jats:italic>PLA2G2D<\/jats:italic>, <jats:italic>MMP9<\/jats:italic>, <jats:italic>PTGDS<\/jats:italic>, <jats:italic>CCL19<\/jats:italic>, <jats:italic>NFIB<\/jats:italic>, <jats:italic>YAP1<\/jats:italic>, <jats:italic>RGL1<\/jats:italic>, and <jats:italic>TIMP3<\/jats:italic> were identified. Kaplan\u2013Meier analysis and multivariate COX regression analysis indicated that <jats:italic>CCL19<\/jats:italic> independently associated with overall survival (OS) for FL patients treated with rituximab and chemotherapy (HR\u2009=\u20090.47, 95% CI [0.25\u20130.86], p\u2009=\u20090.014). Higher serum CCL19 concentration was associated with longer progression-free survival (PFS, p\u2009=\u20090.014) and OS (p\u2009=\u20090.039). TIICs subset analysis showed that CCL19 expression had a positive correlation with monocytes and macrophages M1, and a negative correlation with na\u00efve B cells and plasma cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p><jats:italic>CCL19<\/jats:italic> expression was associated with survival outcomes and might be a potential prognostic biomarker for FL treated with first-line chemoimmunotherapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-021-03078-9","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T15:03:05Z","timestamp":1632150185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapy"],"prefix":"10.1186","volume":"19","author":[{"given":"Yu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shasha","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunxia","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haizhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianliang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Gui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhishang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiarui","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-4964","authenticated-orcid":false,"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,20]]},"reference":[{"key":"3078_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443\u201359. https:\/\/doi.org\/10.3322\/caac.21357.","journal-title":"CA Cancer J Clin"},{"key":"3078_CR2","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569.","journal-title":"Blood"},{"key":"3078_CR3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1200\/jco.1995.13.1.140","volume":"13","author":"PW Johnson","year":"1995","unstructured":"Johnson PW, Rohatiner AZ, Whelan JS, Price CG, Love S, Lim J, Matthews J, Norton AJ, Amess JA, Lister TA. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol. 1995;13:140\u20137. https:\/\/doi.org\/10.1200\/jco.1995.13.1.140.","journal-title":"J Clin Oncol"},{"key":"3078_CR4","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417\u201323. https:\/\/doi.org\/10.1182\/blood-2004-08-3175.","journal-title":"Blood"},{"key":"3078_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/s0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, L\u00f3pez-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42\u201351. https:\/\/doi.org\/10.1016\/s0140-6736(10)62175-7.","journal-title":"Lancet"},{"key":"3078_CR6","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/jco.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, Hainsworth JD, Maurer MJ, Cerhan JR, Link BK, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study. J Clin Oncol. 2015;33:2516\u201322. https:\/\/doi.org\/10.1200\/jco.2014.59.7534.","journal-title":"J Clin Oncol"},{"key":"3078_CR7","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/s1470-2045(15)00169-2","volume":"16","author":"A Pastore","year":"2015","unstructured":"Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, Pott C, Kopp N, Murakami M, Horn H, et al. Integration of gene mutations in risk prognostication for patients receiving first-line chemoimmunotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16:1111\u201322. https:\/\/doi.org\/10.1016\/s1470-2045(15)00169-2.","journal-title":"Lancet Oncol"},{"key":"3078_CR8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/s1470-2045(18)30102-5","volume":"19","author":"S Huet","year":"2018","unstructured":"Huet S, Tesson B, Jais JP, Feldman AL, Magnano L, Thomas E, Traverse-Glehen A, Albaud B, Carr\u00e8re M, Xerri L, et al. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol. 2018;19:549\u201361. https:\/\/doi.org\/10.1016\/s1470-2045(18)30102-5.","journal-title":"Lancet Oncol"},{"key":"3078_CR9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 2008;9:559. https:\/\/doi.org\/10.1186\/1471-2105-9-559.","journal-title":"BMC Bioinform"},{"key":"3078_CR10","doi-asserted-by":"publisher","first-page":"i11","DOI":"10.18637\/jss.v046.i11","volume":"46","author":"P Langfelder","year":"2012","unstructured":"Langfelder P, Horvath S. Fast R functions for robust correlations and hierarchical clustering. J Stat Softw. 2012;46:i11.","journal-title":"J Stat Softw."},{"key":"3078_CR11","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1158\/1078-0432.Ccr-20-2166","volume":"27","author":"Y Chen","year":"2021","unstructured":"Chen Y, Li ZY, Zhou GQ, Sun Y. An Immune-related gene prognostic index for head and neck squamous cell carcinoma. Clin Cancer Res. 2021;27:330\u201341. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-2166.","journal-title":"Clin Cancer Res"},{"key":"3078_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010037","author":"M Niemira","year":"2019","unstructured":"Niemira M, Collin F, Szalkowska A, Bielska A, Chwialkowska K, Reszec J, Niklinski J, Kwasniewski M, Kretowski A. Molecular signature of subtypes of non-small-cell lung cancer by large-scale transcriptional profiling: identification of key modules and genes by weighted gene co-expression network analysis (WGCNA). Cancers. 2019. https:\/\/doi.org\/10.3390\/cancers12010037.","journal-title":"Cancers."},{"key":"3078_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3389\/fonc.2020.00223","volume":"10","author":"H Liu","year":"2020","unstructured":"Liu H, Liu M, You H, Li X, Li X. Oncogenic network and hub genes for natural killer\/t-cell lymphoma utilizing WGCNA. Front Oncol. 2020;10:223. https:\/\/doi.org\/10.3389\/fonc.2020.00223.","journal-title":"Front Oncol"},{"key":"3078_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/bioinformatics\/btg405","volume":"20","author":"L Gautier","year":"2004","unstructured":"Gautier L, Cope L, Bolstad BM, Irizarry RA. affy\u2013analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20:307\u201315. https:\/\/doi.org\/10.1093\/bioinformatics\/btg405.","journal-title":"Bioinformatics"},{"key":"3078_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43: e47. https:\/\/doi.org\/10.1093\/nar\/gkv007.","journal-title":"Nucleic Acids Res"},{"key":"3078_CR16","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284\u20137. https:\/\/doi.org\/10.1089\/omi.2011.0118.","journal-title":"OMICS"},{"key":"3078_CR17","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350. https:\/\/doi.org\/10.1073\/pnas.0506580102.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3078_CR18","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1093\/bioinformatics\/btv300","volume":"31","author":"W Walter","year":"2015","unstructured":"Walter W, S\u00e1nchez-Cabo F, Ricote M. GOplot: an R package for visually combining expression data with functional analysis. Bioinformatics. 2015;31:2912\u20134. https:\/\/doi.org\/10.1093\/bioinformatics\/btv300.","journal-title":"Bioinformatics"},{"key":"3078_CR19","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498\u2013504. https:\/\/doi.org\/10.1101\/gr.1239303.","journal-title":"Genome Res"},{"key":"3078_CR20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453\u20137. https:\/\/doi.org\/10.1038\/nmeth.3337.","journal-title":"Nat Methods"},{"key":"3078_CR21","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.3324\/haematol.2018.209031","volume":"104","author":"A Silva","year":"2019","unstructured":"Silva A, Bassim S, Sarkozy C, Mottok A, Lackraj T, Jurinovic V, Brodtkorb M, Lingjaerde OC, Sehn LH, Gascoyne RD, et al. Convergence of risk prediction models in follicular lymphoma. Haematologica. 2019;104:e252\u20135. https:\/\/doi.org\/10.3324\/haematol.2018.209031.","journal-title":"Haematologica"},{"key":"3078_CR22","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.6093263","volume":"226","author":"Y Tsujimoto","year":"1984","unstructured":"Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984;226:1097\u20139. https:\/\/doi.org\/10.1126\/science.6093263.","journal-title":"Science"},{"key":"3078_CR23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1182\/blood-2017-08-737361","volume":"131","author":"MR Green","year":"2018","unstructured":"Green MR. Chromatin modifying gene mutations in follicular lymphoma. Blood. 2018;131:595\u2013604. https:\/\/doi.org\/10.1182\/blood-2017-08-737361.","journal-title":"Blood"},{"key":"3078_CR24","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1182\/blood-2013-05-500264","volume":"123","author":"H Li","year":"2014","unstructured":"Li H, Kaminski MS, Li Y, Yildiz M, Ouillette P, Jones S, Fox H, Jacobi K, Saiya-Cork K, Bixby D, et al. Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Blood. 2014;123:1487\u201398. https:\/\/doi.org\/10.1182\/blood-2013-05-500264.","journal-title":"Blood"},{"key":"3078_CR25","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1182\/blood-2014-06-582650","volume":"125","author":"M Yildiz","year":"2015","unstructured":"Yildiz M, Li H, Bernard D, Amin NA, Ouillette P, Jones S, Saiya-Cork K, Parkin B, Jacobi K, Shedden K, et al. Activating STAT6 mutations in follicular lymphoma. Blood. 2015;125:668\u201379. https:\/\/doi.org\/10.1182\/blood-2014-06-582650.","journal-title":"Blood"},{"key":"3078_CR26","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/ng.3473","volume":"48","author":"J Okosun","year":"2016","unstructured":"Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Al Seraihi AF, Richter J, Bernhart SH, et al. Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nat Genet. 2016;48:183\u20138. https:\/\/doi.org\/10.1038\/ng.3473.","journal-title":"Nat Genet"},{"key":"3078_CR27","doi-asserted-by":"publisher","first-page":"5383","DOI":"10.1158\/1078-0432.Ccr-16-0609","volume":"22","author":"ZX Ying","year":"2016","unstructured":"Ying ZX, Jin M, Peterson LF, Bernard D, Saiya-Cork K, Yildiz M, Wang S, Kaminski MS, Chang AE, Klionsky DJ, et al. Recurrent mutations in the MTOR regulator RRAGC in follicular lymphoma. Clin Cancer Res. 2016;22:5383\u201393. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-0609.","journal-title":"Clin Cancer Res"},{"key":"3078_CR28","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/leu.2016.232","volume":"31","author":"F Linke","year":"2017","unstructured":"Linke F, Harenberg M, Nietert MM, Zaunig S, von Bonin F, Arlt A, Szczepanowski M, Weich HA, Lutz S, Dullin C, et al. Microenvironmental interactions between endothelial and lymphoma cells: a role for the canonical WNT pathway in Hodgkin lymphoma. Leukemia. 2017;31:361\u201372. https:\/\/doi.org\/10.1038\/leu.2016.232.","journal-title":"Leukemia"},{"key":"3078_CR29","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1084\/jem.193.9.1105","volume":"193","author":"ES Baekkevold","year":"2001","unstructured":"Baekkevold ES, Yamanaka T, Palframan RT, Carlsen HS, Reinholt FP, von Andrian UH, Brandtzaeg P, Haraldsen G. The CCR7 ligand elc (CCL19) is transcytosed in high endothelial venules and mediates T cell recruitment. J Exp Med. 2001;193:1105\u201312. https:\/\/doi.org\/10.1084\/jem.193.9.1105.","journal-title":"J Exp Med"},{"key":"3078_CR30","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1182\/blood.v99.8.2977","volume":"99","author":"KJ Till","year":"2002","unstructured":"Till KJ, Lin K, Zuzel M, Cawley JC. The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood. 2002;99:2977\u201384. https:\/\/doi.org\/10.1182\/blood.v99.8.2977.","journal-title":"Blood"},{"key":"3078_CR31","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1182\/blood.v99.4.1109","volume":"99","author":"UE H\u00f6pken","year":"2002","unstructured":"H\u00f6pken UE, Foss HD, Meyer D, Hinz M, Leder K, Stein H, Lipp M. Up-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs. Blood. 2002;99:1109\u201316. https:\/\/doi.org\/10.1182\/blood.v99.4.1109.","journal-title":"Blood"},{"key":"3078_CR32","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1046\/j.1365-2141.2001.03145.x","volume":"115","author":"H Husson","year":"2001","unstructured":"Husson H, Carideo EG, Cardoso AA, Lugli SM, Neuberg D, Munoz O, de Leval L, Schultze J, Freedman AS. MCP-1 modulates chemotaxis by follicular lymphoma cells. Br J Haematol. 2001;115:554\u201362. https:\/\/doi.org\/10.1046\/j.1365-2141.2001.03145.x.","journal-title":"Br J Haematol"},{"key":"3078_CR33","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1182\/blood-2006-05-020800","volume":"109","author":"P Am\u00e9-Thomas","year":"2007","unstructured":"Am\u00e9-Thomas P, Maby-El Hajjami H, Monvoisin C, Jean R, Monnier D, Caulet-Maugendre S, Guillaudeux T, Lamy T, Fest T, Tarte K. Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood. 2007;109:693\u2013702. https:\/\/doi.org\/10.1182\/blood-2006-05-020800.","journal-title":"Blood"},{"key":"3078_CR34","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nri2297","volume":"8","author":"R F\u00f6rster","year":"2008","unstructured":"F\u00f6rster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol. 2008;8:362\u201371. https:\/\/doi.org\/10.1038\/nri2297.","journal-title":"Nat Rev Immunol"},{"key":"3078_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12041036","author":"B Rizeq","year":"2020","unstructured":"Rizeq B, Malki MI. The role of CCL21\/CCR7 chemokine axis in breast cancer progression. Cancers. 2020. https:\/\/doi.org\/10.3390\/cancers12041036.","journal-title":"Cancers."},{"key":"3078_CR36","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1007\/s13577-020-00375-1","volume":"33","author":"R Zhou","year":"2020","unstructured":"Zhou R, Sun J, He C, Huang C, Yu H. CCL19 suppresses gastric cancer cell proliferation, migration, and invasion through the CCL19\/CCR7\/AIM2 pathway. Hum Cell. 2020;33:1120\u201332. https:\/\/doi.org\/10.1007\/s13577-020-00375-1.","journal-title":"Hum Cell"},{"key":"3078_CR37","doi-asserted-by":"publisher","first-page":"73817","DOI":"10.18632\/oncotarget.17982","volume":"8","author":"X Zhang","year":"2017","unstructured":"Zhang X, Wang Y, Cao Y, Zhang X, Zhao H. Increased CCL19 expression is associated with progression in cervical cancer. Oncotarget. 2017;8:73817\u201325. https:\/\/doi.org\/10.18632\/oncotarget.17982.","journal-title":"Oncotarget"},{"key":"3078_CR38","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ccell.2019.08.001","volume":"36","author":"T O'Connor","year":"2019","unstructured":"O\u2019Connor T, Zhou X, Kosla J, Adili A, Garcia Beccaria M, Kotsiliti E, Pfister D, Johlke AL, Sinha A, Sankowski R, et al. Age-related gliosis promotes central nervous system lymphoma through CCL19-mediated tumor cell retention. Cancer Cell. 2019;36:250-267.e259. https:\/\/doi.org\/10.1016\/j.ccell.2019.08.001.","journal-title":"Cancer Cell"},{"key":"3078_CR39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1756-9966-30-51","volume":"30","author":"J Yang","year":"2011","unstructured":"Yang J, Wang S, Zhao G, Sun B. Effect of chemokine receptors CCR7 on disseminated behavior of human T cell lymphoma: clinical and experimental study. J Exp Clin Cancer Res. 2011;30:51. https:\/\/doi.org\/10.1186\/1756-9966-30-51.","journal-title":"J Exp Clin Cancer Res"},{"key":"3078_CR40","doi-asserted-by":"publisher","first-page":"424","DOI":"10.4049\/jimmunol.169.1.424","volume":"169","author":"SA Luther","year":"2002","unstructured":"Luther SA, Bidgol A, Hargreaves DC, Schmidt A, Xu Y, Paniyadi J, Matloubian M, Cyster JG. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J Immunol. 2002;169:424\u201333. https:\/\/doi.org\/10.4049\/jimmunol.169.1.424.","journal-title":"J Immunol"},{"key":"3078_CR41","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/ni1513","volume":"8","author":"A Link","year":"2007","unstructured":"Link A, Vogt TK, Favre S, Britschgi MR, Acha-Orbea H, Hinz B, Cyster JG, Luther SA. Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. Nat Immunol. 2007;8:1255\u201365. https:\/\/doi.org\/10.1038\/ni1513.","journal-title":"Nat Immunol"},{"key":"3078_CR42","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1189\/jlb.1A0314-170R","volume":"97","author":"W Xuan","year":"2015","unstructured":"Xuan W, Qu Q, Zheng B, Xiong S, Fan GH. The chemotaxis of M1 and M2 macrophages is regulated by different chemokines. J Leukoc Biol. 2015;97:61\u20139. https:\/\/doi.org\/10.1189\/jlb.1A0314-170R.","journal-title":"J Leukoc Biol"},{"key":"3078_CR43","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1158\/1078-0432.Ccr-09-2487","volume":"16","author":"BE Wahlin","year":"2010","unstructured":"Wahlin BE, Aggarwal M, Montes-Moreno S, Gonzalez LF, Roncador G, Sanchez-Verde L, Christensson B, Sander B, Kimby E. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1\u2013positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res. 2010;16:637\u201350. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-09-2487.","journal-title":"Clin Cancer Res"},{"key":"3078_CR44","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1158\/1078-0432.Ccr-13-2367","volume":"20","author":"JP Smeltzer","year":"2014","unstructured":"Smeltzer JP, Jones JM, Ziesmer SC, Grote DM, Xiu B, Ristow KM, Yang ZZ, Nowakowski GS, Feldman AL, Cerhan JR, et al. Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma. Clin Cancer Res. 2014;20:2862\u201372. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-2367.","journal-title":"Clin Cancer Res"},{"key":"3078_CR45","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.critrevonc.2016.10.006","volume":"108","author":"D Galati","year":"2016","unstructured":"Galati D, Corazzelli G, De Filippi R, Pinto A. Dendritic cells in hematological malignancies. Crit Rev Oncol Hematol. 2016;108:86\u201396. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.10.006.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3078_CR46","doi-asserted-by":"publisher","first-page":"6666","DOI":"10.1158\/1078-0432.Ccr-07-0504","volume":"13","author":"KC Chang","year":"2007","unstructured":"Chang KC, Huang GC, Jones D, Lin YH. Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses. Clin Cancer Res. 2007;13:6666\u201372. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-0504.","journal-title":"Clin Cancer Res"},{"key":"3078_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114345","volume":"9","author":"CS Tudor","year":"2014","unstructured":"Tudor CS, Bruns H, Daniel C, Distel LV, Hartmann A, Gerbitz A, Buettner MJ. Macrophages and dendritic cells as actors in the immune reaction of classical Hodgkin lymphoma. PLoS ONE. 2014;9: e114345. https:\/\/doi.org\/10.1371\/journal.pone.0114345.","journal-title":"PLoS ONE"},{"key":"3078_CR48","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. 2018;36:346\u201351. https:\/\/doi.org\/10.1038\/nbt.4086.","journal-title":"Nat Biotechnol"},{"key":"3078_CR49","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00262-020-02577-w","volume":"69","author":"MC Cox","year":"2020","unstructured":"Cox MC, Lapenta C, Santini SM. Advances and perspectives of dendritic cell-based active immunotherapies in follicular lymphoma. Cancer Immunol Immunother. 2020;69:913\u201325. https:\/\/doi.org\/10.1007\/s00262-020-02577-w.","journal-title":"Cancer Immunol Immunother"},{"key":"3078_CR50","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","volume":"379","author":"R Advani","year":"2018","unstructured":"Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, et al. CD47 Blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma. N Engl J Med. 2018;379:1711\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1807315.","journal-title":"N Engl J Med"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-021-03078-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-021-03078-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-021-03078-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T15:13:13Z","timestamp":1632150793000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-021-03078-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,20]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3078"],"URL":"https:\/\/doi.org\/10.1186\/s12967-021-03078-9","relation":{},"ISSN":["1479-5876"],"issn-type":[{"type":"electronic","value":"1479-5876"}],"subject":[],"published":{"date-parts":[[2021,9,20]]},"assertion":[{"value":"7 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study of pre-treatment serum samples from patients was approved by the medical ethics committee of Cancer Hospital, CAMS & PUMC (No. 19\/088-1873).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interest exists.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"399"}}